An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial

The efficacy of immune checkpoint inhibitors has been shown to depend on preexisting antitumor immunity; thus, their combination with cancer vaccines is an attractive therapeutic approach. Plasmacytoid dendritic cells (PDC) are strong inducers of antitumor responses and represent promising vaccine c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Charles, Julie, Chaperot, Laurence, Hannani, Dalil, Bruder Costa, Juliana, Templier, Isabelle, Trabelsi, Sabiha, Gil, Hugo, Moisan, Anaick, Persoons, Virginie, Hegelhofer, Harald, Schir, Edith, Quesada, Jean-Louis, Mendoza, Christophe, Aspord, Caroline, Manches, Olivier, Coulie, Pierre G., Khammari, Amir, Dreno, Brigitte, Leccia, Marie-Thérèse, Plumas, Joel
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7153838/
https://ncbi.nlm.nih.gov/pubmed/32313721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1738812
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars